InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,426.40
(
0.12%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.80
(
0.02%
)
Bitcoin
65,054.23
(
-0.14%
)
Post# of 252254
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119875
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 156480

Wednesday, 02/06/2013 4:34:45 PM

Wednesday, February 06, 2013 4:34:45 PM

Post# of 252254

GILD—Yes, but will the FDA approve it?

My reply in #msg-84225008 didn’t give a yes or no answer because I don’t think GILD will include genotype-3 in the Sofusbuvir/ribavirin NDA submission if they can’t do better than the 56% SVR seen in FISSION. Rather, they will submit an NDA for genotypes-1 and -2 and deal with genotype-3 in a subsequent filing.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up